NHS England has been able to finalise this negotiation because the company agreed confidential commercial terms that constitute good value for British taxpayers and agreed to submit its drugs for full NICE appraisal. The agreement provides access to all three drugs for all current licensed indications, as well as future licence extensions too. There is no cap on patient numbers, and each and every patient in England who might benefit can now get these treatments, free on the NHS. Clinicians will be able to begin prescribing these drugs within 30 days.
Letter from NHS Chief Executive Simon Stevens to the chair of Parliament’s Health and Social Care Committee sets out more detail on these drugs.